Protein Kinase Inhibitors: all 15,766 studies that test it

Page 21 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.RecruitingNCT05609630Phase 3
• A Study Evaluating SYHX2005 in the Treatment of Patients With Advanced Solid TumorsNot yet recruitingNCT05609019Phase 1
• VS-6766+Abema+Fulv in Met HR+/HER- BCRecruitingNCT05608252Phase 1/2
• Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial CarcinomaRecruitingNCT05603910Phase 1
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaRecruitingNCT05602363Phase 1
• Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2
• Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System LymphomaRecruitingNCT05600660Phase 2
• Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT ModelRecruitingNCT05599256Phase 2
• Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial RemissionNot yet recruitingNCT05596097Phase 2
• Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNot yet recruitingNCT05595889Phase 2
• SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
• A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN LossRecruitingNCT05593497Phase 2
• Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic LeukemiaRecruitingNCT05592015Phase 2
• A Study of Sulfatinib on Relapsed or Refractory Drug Resistant OsteosarcomaNot yet recruitingNCT05590572Phase 1/2
• Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive OsteosarcomaRecruitingNCT05588648Phase 1/2
• 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) MutationsRecruitingNCT05588141Phase 1/2
• Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingNCT05582538Phase 2
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
• ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)RecruitingNCT05580562Phase 3
• Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic CancerRecruitingNCT05580445Phase 1/2
• Study of Trilaciclib and LurbinectidinRecruitingNCT05578326Phase 2
• Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)Not yet recruitingNCT05577923Phase 2
• Assessment of the Efficacy and Safety of Alpelisib (BYL719) in Pediatric and Adult Patients With Megalencephaly-CApillary Malformation Polymicrogyria Syndrome (MCAP)RecruitingNCT05577754Phase 2
• GQ1001 Combined With Pyrotinib for Treatment With HER2 Positive Metastatic Breast CancerRecruitingNCT05575804Phase 1/2
• MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingNCT05564390Phase 2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
• Masitinib in Patients With Mild Alzheimer's DiseaseNot yet recruitingNCT05564169Phase 3
• A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR AlterationsRecruitingNCT05560334Phase 2
• Phase II Clinical Study of T-DM1 and Pyrotinib Maleate in Patients With HER2-positive Metastatic Breast Cancer Who Had Progressed on TKI TherapyNot yet recruitingNCT05560308Not applicable
• A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastrointestinal Cancer (Excluding Biliary Tract Cancer) Patients With FGFR Alterations Who Have Failed Standard TherapyRecruitingNCT05559775Phase 2
• Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)RecruitingNCT05559645Not applicable
• A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
• A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsRecruitingNCT05556200Phase 2
• The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal CancerRecruitingNCT05555901Phase 2
• To Evaluate the Efficacy of QLH11811 in Advanced NSCLC Patients With EGFR MutationRecruitingNCT05555212Phase 1
• H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLCRecruitingNCT05552781Phase 1/2
• Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)RecruitingNCT05552755Phase 1/2
• Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial CancerNot yet recruitingNCT05550558Phase 2
• Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap NeoplasmsRecruitingNCT05549661Phase 1
• Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCRecruitingNCT05549466Phase 2
• Efficacy and Safety of Sirolimus in Children and Adolescents With Juvenile Nasopharyngeal Angiofibroma (JNA)RecruitingNCT05549167Phase 3
• First-line Furmonertinib in Advanced NSCLC Patients With EGFR Uncommon MutationRecruitingNCT05548348Phase 2
• ONC201 and Atezolizumab in Obesity-Driven Endometrial CancerRecruitingNCT05542407Phase 1
• To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET DysregulationRecruitingNCT05541822Phase 2
• Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable MelanomaNot yet recruitingNCT05539118Phase 1/2
• Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)RecruitingNCT05536349Phase 2
• Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCCRecruitingNCT05533892Phase 1
• Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC PatientsRecruitingNCT05532696Phase 1/2
• Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced CholangiocarcinomaRecruitingNCT05532059Phase 2
• Phase I/II Study of Pacritinib, A JAK2/IRAK1/CSF1R Inhibitor, in Refractory Chronic Graft-Versus-Host Disease (cGVHD) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)RecruitingNCT05531786Phase 1/2
• Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) PatientsRecruitingNCT05529069Phase 2
• Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaRecruitingNCT05528458Phase 2
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Solid Tumor Patients With BRAF V600 MutationNot yet recruitingNCT05528406Phase 2
• Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid TumorsNot yet recruitingNCT05527821Phase 2
• Tamoxifen Prediction Study in Patients With ER+ Breast CancerRecruitingNCT05525481Phase 4
• Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib BloodlevelsRecruitingNCT05525338Phase 4
• Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different GenotypesNot yet recruitingNCT05524974Phase 2
• Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast CancerRecruitingNCT05524584Phase 2
• Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal CancerRecruitingNCT05522738Phase 1/2
• FGFR Inhibitor ET0111 Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT05522309Phase 1
• Olverembatinib for FGFR1-rearranged NeoplasmsRecruitingNCT05521204Phase 2
• Study to Evaluate the Efficacy of Afatinib in Skull Base ChordomaNot yet recruitingNCT05519917Phase 2
• Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular CarcinomaRecruitingNCT05519410Phase 2
• Phase I/IIa Study of H002 in NSCLC With Active EGFR MutationRecruitingNCT05519293Phase 1/2
• A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete ResectionNot yet recruitingNCT05514314Phase 2
• A Phase 2 Study of Avutometinib (VS-6766) Plus DefactinibRecruitingNCT05512208Phase 2
• A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid TumorsNot yet recruitingNCT05508659Phase 1/2
• Zanubrutinib-rituximab(ZR) in Patients With Newly Diagnosed Untreated Mantle Cell LymphomaRecruitingNCT05504603Phase 2
• A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 2
• Januse Kinase Inhibition With Filgotinib to Silence Autoreactive B Cells in Rheumatoid ArthritisNot yet recruitingNCT05502731Phase 4
• ETHAN - ET for Male BCRecruitingNCT05501704Phase 2
• A First-in-Human, Phase 1 Study of SY-4798 in Patients With Advanced Solid TumorRecruitingNCT05498519Phase 1
• EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung CancerNot yet recruitingNCT05498389Phase 1/2
• Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingNCT05495035Phase 1
• XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction AdenocarcinomaRecruitingNCT05494060Phase 2
• Imatinib TDM in GISTRecruitingNCT05493215Phase 2
• Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic LymphohistiocytosisRecruitingNCT05491304Phase 4
• A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to IbrutinibRecruitingNCT05491044Phase 2
• Clinical Study of Anlotinib Combined With Chemotherapy in the Treatment of Unresectable Advanced Desmoid TumorRecruitingNCT05490667Not applicable
• JAB-2485 Activity in Adult Patients With Advanced Solid TumorsRecruitingNCT05490472Phase 1/2
• VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung CancerRecruitingNCT05489731Phase 1
• Safety, Tolerability and Pharmacokinetics Study of QLH11906 in Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations.RecruitingNCT05488821Phase 1
• A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung CancerRecruitingNCT05482568Phase 1/2
• A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLCNot yet recruitingNCT05482087Phase 2
• Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT05479487Phase 2
• Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0RecruitingNCT05476939Phase 3
• Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix CarcinomaRecruitingNCT05472948Phase 2
• Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor PatientsRecruitingNCT05468359Phase 1/2
• Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast CancerRecruitingNCT05467891Phase 2
• A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-InfectionNot yet recruitingNCT05467553Phase 2
• Tovorafenib for Treatment of Craniopharyngioma in Children and Young AdultsRecruitingNCT05465174Phase 2
• Chidamide in Combination With Abemaciclib and Endocrinotherapy（Doctor's Choice） in Breast Cancer Patients Previously Treated With PalbociclibRecruitingNCT05464173Phase 1/2
• Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal CancerRecruitingNCT05462613Phase 2/3
• Sirolimus in Cutaneous SarcoidosisNot yet recruitingNCT05458492Phase 2
• Baricitinib for Reduction of HIV - CNSRecruitingNCT05452564Phase 2
• Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer PatientsRecruitingNCT05452213Phase 4
• Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line ChemotherapyNot yet recruitingNCT05451719Phase 2
• Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung CancerRecruitingNCT05450965Phase 2
• Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingNCT05447702Phase 2
• Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung CancerRecruitingNCT05445310Phase 2

← Protein Kinase Inhibitors overview